Table 2. Univariate analyses of predictors of invasive carcinomas derived from mucinous pancreatic cystic neoplasms.
| Characteristic, n (%) | Low-/moderate-grade dysplasia (n = 148) | High-grade dysplasia (n = 48) | Invasive carcinoma (n = 49) | Non-invasive vs invasive, P |
|---|---|---|---|---|
| Age ≥ 61 years | 44 (29.7%) | 34 (70.8%) | 29 (59.2%) | 0.014 |
| Male | 43 (29.1%) | 29 (60.4%) | 24 (49.0%) | 0.116 |
| Symptom, present | 62 (41.9%) | 23 (47.9%) | 31 (63.3%) | 0.013 |
| Tumor size ≥ 49 mm | 45 (30.4%) | 11 (22.9%) | 25 (51.0%) | 0.003 |
| MPD diameter ≥ 10 mm | 6 (4.1%) | 9 (18.8%) | 13 (26.5%) | < 0.001 |
| Pathology | 0.001 | |||
| IPMN | 73 (49.3%) | 47 (97.9%) | 42 (85.7%) | |
| MCN | 75 (50.7%) | 1 (2.1%) | 7 (14.3%) | |
| IPMN classification | 0.014 | |||
| Main duct | 20 (27.4%) | 17 (36.2%) | 18 (42.9%) | |
| Mixed type | 12 (16.4%) | 11 (23.4%) | 12 (28.6%) | |
| Branch duct | 36 (49.3%) | 15 (31.9%) | 7 (16.7%) | |
| Unknown | 5 (6.8%) | 4 (8.5%) | 5 (11.9%) | |
| Albumin ≤ 39 g/L | 50 (33.8%) | 24 (50.0%) | 25 (51.0%) | 0.091 |
| CA19-9 ≥ 42.7 U/mL* | 12 (8.6%) | 6 (12.8%) | 19 (38.8%) | < 0.001 |
| CEA ≥ 1.9 ng/mL# | 55 (39.9%) | 29 (61.7%) | 40 (81.6%) | < 0.001 |
| Neutrophil count ≥ 2.8 ×109/L | 77 (52.0%) | 28 (58.3%) | 35 (71.4%) | 0.024 |
| Lymphocyte count ≤ 1.9 ×109/L | 59 (39.9%) | 22 (45.8%) | 7 (14.3%) | < 0.001 |
| PLR ≥ 125 | 45 (30.4%) | 15 (31.3%) | 32 (65.3%) | < 0.001 |
| NLR ≥ 1.96 | 34 (23.0%) | 12 (25.0%) | 28 (57.1%) | < 0.001 |
| LMR ≤ 4.29 | 41 (27.7%) | 16 (33.3%) | 32 (65.3%) | < 0.001 |
MPD, main pancreatic duct; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; WBC, white blood cell; PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; *, n = 235; #, n = 234.